Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: October 3, 2014
Event: Entry into a Definitive Material Agreement (Commercial Supply Agreement).
Key Financial Metrics
This filing reports a strategic commercial agreement and does not contain financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, or liquidity are not provided in this document.
Material Changes and Agreement Terms
On October 3, 2014, Omeros Corporation entered into a Commercial Supply Agreement with Hospira S.p.A. and Hospira Worldwide, Inc. Key terms include:
- Product: OmidriaTM.
- Role: Hospira acts as a non-exclusive supplier for commercial sale in the United States and the European Union (EU).
- United States: Hospira agreed to manufacture and supply a minimum percentage of Omeros' requirements for commercial sales and clinical supplies.
- European Union: Upon marketing approval, Hospira agreed to supply a portion of requirements (mutually agreed, not exceeding a maximum percentage) within four months. No minimum purchase requirement exists if parties do not reach an agreement within this timeframe.
- Forecasting: Omeros must provide rolling, non-binding long-term forecasts and monthly rolling forecasts to calculate firm purchase commitments.
- Term: Initial term of five years from the date of first commercial sale in the Territory, with automatic renewal for up to two additional one-year periods.
- Termination: May be terminated by mutual consent or upon specified events (e.g., uncured breach, bankruptcy). Upon termination (except for Hospira's uncured breach), Omeros must purchase Hospira's inventory, work in progress, and reimburse for supplies based on firm orders or estimates.
Guidance, Outlook, and Risks
Outlook: The agreement facilitates the commercial processing and supply of Omidria in key markets (US and EU).
Risks/Contingencies:
- Financial obligation to purchase inventory and reimburse supplies upon termination of the agreement.
- Uncertainty regarding the specific percentage of EU requirements if parties fail to agree within four months of marketing approval.
- Dependence on Hospira for manufacturing and supply capabilities.
Investor Verification Checklist
- Verify the specific "minimum percentage" of Omidria requirements Omeros is obligated to purchase in the US.
- Confirm the status of marketing approval for Omidria in the European Union to trigger EU supply terms.
- Review the full text of the Supply Agreement for detailed termination clauses and inventory valuation methods.
- Assess Hospira's manufacturing capacity and financial stability as a non-exclusive supplier.